Poxel
POXEL.PAPhase 2Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, with a focus on non-alcoholic steatohepatitis (NASH) and rare disorders.
Market Cap
$15.5M
Founded
2021
Focus
Small Molecules
POXEL.PA · Stock Price
USD 0.251.82 (-87.89%)
Historical price data
About
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, with a focus on non-alcoholic steatohepatitis (NASH) and rare disorders.
Pipeline Snapshot
1414 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| PXL065 | ALD (Adrenoleukodystrophy) | Phase 2 |
| PXL770 | Adrenomyeloneuropathy | Phase 2 |
| PXL770 + Placebo Oral Capsule | Nonalcoholic Fatty Liver | Phase 2 |
| PXL065 + Placebo oral tablet | NASH - Nonalcoholic Steatohepatitis | Phase 2 |
| Imeglimin + Placebo | Type 2 Diabetes Mellitus | Phase 2 |
Funding History
4Total raised: $155M
Debt$30MUndisclosedMay 15, 2019
IPO$60MUndisclosedJul 15, 2015
Series B$40MUndisclosedJun 15, 2013
Series A$25MUndisclosedJun 15, 2010
Company Info
TypePublic
Founded2021
LocationLyon, France
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile